Jump to any asset
849 assets, updated daily
As of October 11, 2026, Novo Nordisk A/S Sponsored (NVO) trades at $38.64. CleaRank Financial AI rates it Hold with a fair value of $44.53, 15.2% above the current price. Wall Street's consensus target is $44.53 across 14 analysts. RSI at 39 is in neutral territory, and the price is below its 50-day average of $43.43.
Novo Nordisk A/S Sponsored (NVO)
Novo Nordisk A/S Sponsored NYSE
$38.64
0.4600 (1.20%)
At close: Oct 9, 4:00 PM EDT
AI Analyst Consensus
54 / 100
Novo Nordisk A/S (NVO) is currently trading at $38.64, below its 50-day and 200-day moving averages ($43.43 and $45.40), indicating a bearish technical posture. The company has demonstrated strong historical growth, with a past 5-year compound annual growth rate of 18.6%, but current analyst estimates project a slight revenue contraction of -3.00% for the current year and -1.9% for next year, with a 5-year average growth estimate of 6.7%. This slowdown in projected growth, coupled with a recent downgrade from Morgan Stanley to 'Underweight' and a median Wall Street price target of $44.53, suggests a period of consolidation. Despite the near-term headwinds, Novo Nordisk maintains a strong profit margin of 35.35% and a healthy return on equity of 59.82%, significantly outperforming sector averages. The company's price-to-sales ratio of 0.51 is well below the sector median of 3.7, suggesting potential value. However, the bearish momentum indicated by its RSI of 38.93 and MACD of -1.75 warrants caution. The primary risk revolves around the projected deceleration in revenue growth and the increasing number of analyst downgrades, which could pressure the stock further if not offset by new product catalysts or market share gains.
NVO Price Analysis
Market Metrics
Open
$38.11
Day Range
$38.06 to $38.68
Prev Close
$38.18
Volume
9.61M
52-Week Range
$35.12 to $64.16
Market Cap
$170.57B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-71%), which may indicate undervaluation or specific company headwinds.
NVO Financial Performance
Revenue vs. Earnings
Annual
Quarterly
NVO Analysis
Company's Health
4/5
12-Month Analyst Target
+15.24% Upside
Median of 14 analysts (12-month)
$44.53
AI Technical Analysis
Novo Nordisk A/S exhibits bearish momentum, trading below its 50-day and 200-day moving averages ($43.43 and $45.40), with its 50-day SMA acting as resistance. The Relative Strength Index (RSI) at 38.93 confirms this bearish sentiment, indicating weak momentum. The Moving Average Convergence Divergence (MACD) is also negative at -1.75, reinforcing the downward trend. Volume has been below average recently, with the latest volume at 9.61 million compared to an average of 13.28 million, suggesting a lack of conviction behind the current price action. Key support levels are not clearly defined due to the limited trading history and recent price action, but the current price of $38.64 is approaching the lower end of its recent trading range. Investors should monitor for any potential bounce off oversold territory or a confirmed break above the 50-day SMA for signs of a trend reversal.
ProTips
- Monitor upcoming earnings reports closely for any signs of revenue acceleration or further deceleration, as this will be a key driver of future performance.
- The stock is trading below its 50-day and 200-day moving averages ($43.43 and $45.40), indicating bearish momentum. Consider waiting for a confirmed break above these levels before initiating new positions.
- Given the projected revenue slowdown, focus on companies with stronger forward growth estimates within the Healthcare sector for potentially higher returns.
Key Catalysts
Bearish
Analyst Downgrades Signal Shifting Sentiment
Recent downgrades from major firms like Morgan Stanley ('Underweight') and Goldman Sachs ('Neutral') suggest a reassessment of Novo Nordisk's growth prospects and potential headwinds.
Source: Wall Street Analyst RatingsBearish
Projected Revenue Contraction
Current analyst estimates forecast a -3.00% revenue decline for the current year and -1.9% for next year, indicating a significant slowdown compared to historical performance.
Source: Wall Street Revenue EstimatesNeutral
Dividend Payout Continues
Novo Nordisk offers a dividend yield of approximately 4.80%, providing some return to shareholders even amidst projected growth challenges.
Source: Company FinancialsBullish
Strong Profitability and Margins
The company maintains exceptional profit margins (35.35%) and return on equity (59.82%), indicating operational efficiency and strong underlying business health.
Source: Company FundamentalsMarket Outlook
The base case scenario for Novo Nordisk A/S anticipates a period of stabilization and potential recovery, with the median Wall Street price target suggesting an upside of 15.2% to $44.53. While current revenue growth projections are subdued, the company's strong profitability and attractive valuation relative to sales provide a foundation for future performance. The company's ability to leverage its established market position and potentially introduce new growth drivers will be key to achieving higher valuations. Potential catalysts for upside include successful new product launches or unexpected acceleration in market demand for its existing treatments. Conversely, downside risks include a more pronounced slowdown in revenue growth than anticipated, increased competition, or adverse regulatory changes. The increasing number of analyst downgrades also presents a risk, as further negative sentiment could weigh on the stock price, pushing it towards its lower support levels.
Key Statistics
| Market Cap | 170.57B |
|---|---|
| P/E Ratio | 9.39 |
| EPS (TTM) | 4.09 |
| Dividend Yield | 4.80% |
| 52 Week High | 64.16 |
| 52 Week Low | 35.12 |
Novo Nordisk A/S presents a mixed fundamental picture, trading at a price-to-sales ratio of 0.51, which is substantially lower than the sector median of 3.7, indicating it may be undervalued on a sales basis. The company boasts an exceptional profit margin of 35.35% and a return on equity of 59.82%, far exceeding sector averages of 6.9% for ROE. However, projected revenue growth has turned negative, with estimates showing a -3.00% decline for the current year and a slight +1.00% increase for next year, contrasting sharply with the sector's 8.1% revenue growth average. The company's debt-to-equity ratio stands at 0.63, which is slightly below the sector median of 0.63, suggesting a manageable debt load. While profitability metrics are strong, the projected slowdown in revenue growth and the current bearish technicals raise concerns about the sustainability of its past performance. The valuation appears attractive relative to its sales, but the forward-looking growth prospects need to be closely monitored.
Earnings & Growth Analysis
Novo Nordisk A/S's recent earnings performance shows a mixed trend. For the current quarter, analysts estimate an average EPS of $4.8255, with a projected year-over-year growth of 7.23%. However, revenue estimates for the next quarter indicate a -4.00% year-over-year decline, and for the current year, a -3.00% contraction is expected. This suggests a potential slowdown in top-line growth, which could impact future earnings.
Key Risks
The primary risk for Novo Nordisk A/S lies in its projected deceleration of revenue growth, with current estimates indicating a contraction for the current year. Additionally, a notable shift in analyst sentiment is occurring, with several recent downgrades from 'Buy' or 'Overweight' to 'Hold' or 'Underweight', signaling potential headwinds. The stock's bearish technical indicators, including trading below key moving averages and a low RSI, suggest that further downside pressure is possible in the near term.
Technical Indicators
| RSI (14) | 38.93 |
|---|---|
| MACD | -1.75 |
| SMA 50 | 43.43 |
| SMA 200 | 45.40 |
RSI
Bearish
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $43.43, 200-day: $45.40), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.28
Weak correlation
Nasdaq 100 (QQQ)
+0.22
Weak correlation
Bitcoin (BTC)
+0.34
Weak correlation
Gold (XAU)
+0.04
Weak correlation
Check Custom Correlation
How does any other asset move with NVO? One year of daily closes, Pearson correlation.
Try
NVO Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$38.25
Slight discount to current
Wait for small dip
Aggressive
$38.64
At current price
Enter now if confident
Risk Management
STOP LOSS
$37.01
MAX LOSS
-3.3%
Volatility-Adjusted Stop Loss
Calculated based on RSI (38.9) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$39.40
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$40.17
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$41.31
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for NVO is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on October 11, 2026.Growth of $10,000
A $10,000 investment in NVO in October 2016 would be worth about $19,427 today, compared with about $36,479 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NVO today could grow to about $19,708 by 2036 in the base case, with a bull case near $75,795 and a bear case around $5,124. Projections are statistical simulations, not guarantees.
NVO Stock Price Prediction: 2030
CleaRank's simulation projects a price near $50.69 for NVO by 2030 in the base case, from $38.64 today (1.3x over 4 years). The downside path ends near $21.62. These are outcomes of a Monte Carlo simulation run on NVO's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $27.01 | $41.35 | $63.31 |
| 2028 | $24.23 | $44.26 | $80.83 |
| 2029 | $22.65 | $47.36 | $99.05 |
| 2030 | $21.62 | $50.69 | $119 |
| 2031 | $20.93 | $54.24 | $141 |
| 2032 | $20.45 | $58.05 | $165 |
| 2033 | $20.13 | $62.13 | $192 |
| 2034 | $19.93 | $66.49 | $222 |
| 2035 | $19.83 | $71.16 | $255 |
| 2036 | $19.80 | $76.15 | $293 |
Method: 10,000 simulated price paths using NVO's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
Frequently Asked Questions
What is Novo Nordisk's stock price forecast for 2030?
Based on Monte Carlo simulations, Novo Nordisk's stock price is projected to be $50.69 in 2030 under a base case scenario. The downside projection is $21.62, while the upside projection reaches $118.82. These figures represent statistical outcomes, not guaranteed price targets.
Is Novo Nordisk stock a buy right now?
Novo Nordisk A/S is currently rated 'Hold' by Wall Street analysts with a consensus score of 54 out of 100. The stock is trading below its key moving averages and exhibits bearish momentum, suggesting it may not be an optimal time to buy.
What are Novo Nordisk's recent earnings trends?
For the current quarter, analysts estimate EPS of $4.8255, showing positive growth. However, revenue estimates for the next quarter and current year project a decline, indicating a potential slowdown in top-line performance.
How does Novo Nordisk compare to its sector averages?
Novo Nordisk significantly outperforms sector averages in profitability with a profit margin of 35.35% and a return on equity of 59.82%. However, its projected revenue growth of -3.00% for the current year lags behind the sector's median growth of 8.1%.
What is the outlook for Novo Nordisk's revenue growth?
Current analyst estimates project a revenue contraction of -3.00% for the current year and a modest +1.00% growth for next year. This contrasts with its strong historical growth and suggests a period of slower expansion.
What are the main risks facing Novo Nordisk?
Key risks include the projected slowdown in revenue growth, a recent increase in analyst downgrades, and bearish technical indicators suggesting potential near-term price weakness.
What is Novo Nordisk's dividend yield?
Novo Nordisk A/S has a dividend yield of approximately 4.80% and a dividend rate of $1.85.